Barrón-González Arturo, Castro Romero Ivone
Department of Biochemistry and Molecular Biology, National Institute of Perinatology, Lomas de Virreyes, Mexico City, Mexico.
Biochem Cell Biol. 2004 Apr;82(2):335-42. doi: 10.1139/o03-083.
Estrogen receptor (ER)-negative breast carcinomas are often difficult to treat with antiestrogens. This work was performed to determine if the re-expression of the human ER alpha could restore the hormone response of these cells. We have transfected the human wild-type ER alpha to an ER-negative breast cancer cell line (MDA-MB-231) using a tetracycline-regulated gene expression system. We obtained a new cell line, MDA-A4-5/2. Cell count and flow cytometry "S" phase cell fraction showed that 17-beta-estradiol induced an inhibition on the proliferation of these cells; on the contrary, the antiestrogens ICI 182 780, and tamoxifen blocked this effect. Finally, we demonstrated an induction of the endogenous progesterone receptor gene when ER alpha was present. These results suggest that the re-expression of ER alpha in ER-negative breast cancer cells recreate, at least partially, a hormone-responsive phenotype and may be useful as a therapeutic approach to control this pathology.
雌激素受体(ER)阴性乳腺癌通常难以用抗雌激素药物治疗。开展这项研究是为了确定人ERα的重新表达是否能恢复这些细胞的激素反应。我们使用四环素调控基因表达系统将人野生型ERα转染至ER阴性乳腺癌细胞系(MDA-MB-231)。我们获得了一个新的细胞系MDA-A4-5/2。细胞计数和流式细胞术“S”期细胞分数显示,17-β-雌二醇对这些细胞的增殖有抑制作用;相反,抗雌激素药物ICI 182 780和他莫昔芬可阻断这种作用。最后,我们证明当存在ERα时,内源性孕激素受体基因会被诱导。这些结果表明,ER阴性乳腺癌细胞中ERα的重新表达至少部分地重现了激素反应性表型,并且可能作为控制这种疾病的一种治疗方法。